Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age
NCT ID: NCT03916185
Last Updated: 2025-02-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1/PHASE2
67 participants
INTERVENTIONAL
2019-06-20
2024-04-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age
NCT03227029
Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children
NCT03596801
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children
NCT01893554
Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children
NCT03387137
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
NCT01968083
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants were randomly assigned to receive a single dose of RSV ΔNS2/Δ1313/I1314L vaccine, RSV 6120/ΔNS2/1030s vaccine, RSV 276 vaccine, or placebo intranasally at study entry.
Participants were enrolled in the study outside of RSV season. All participants were to remain on study until they completed the post-RSV season visit in the calendar year following enrollment. Participants' total study duration was expected to be between 5 and 15 months, depending on when they enrolled in the study and accommodations given for the COVID pandemic.
Participants attended several study visits throughout the study, which included physical examinations, blood collection, and nasal washes or swabs, if applicable. Participants' parents or guardians were contacted by study staff at various times during the study to monitor participants' health.
The study closed to enrollment prior to fully accruing due to difficulties with slower than expected accrual.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RSV ΔNS2/Δ1313/I1314L Vaccine
Participants received a single dose of the RSV ΔNS2/Δ1313/I1314L vaccine at study entry (Day 0).
RSV ΔNS2/Δ1313/I1314L Vaccine
10\^6 plaque-forming units (PFU); administered as nose drops
RSV 6120/ΔNS2/1030s Vaccine
Participants received a single dose of the RSV 6120/ΔNS2/1030s vaccine at study entry (Day 0).
RSV 6120/ΔNS2/1030s Vaccine
10\^5 plaque-forming units (PFU); administered as nose drops
RSV 276 Vaccine
Participants received a single dose of the RSV 276 vaccine at study entry (Day 0).
RSV 276 Vaccine
10\^5 plaque-forming units (PFU); administered as nose drops
Placebo
Participants received a single dose of placebo at study entry (Day 0).
Placebo
Administered as nose drops
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RSV ΔNS2/Δ1313/I1314L Vaccine
10\^6 plaque-forming units (PFU); administered as nose drops
RSV 6120/ΔNS2/1030s Vaccine
10\^5 plaque-forming units (PFU); administered as nose drops
RSV 276 Vaccine
10\^5 plaque-forming units (PFU); administered as nose drops
Placebo
Administered as nose drops
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Parent/guardian is willing and able to provide written informed consent as described in the study protocol.
* Seronegative for RSV antibody, defined as a serum RSV-neutralizing antibody titer less than 1:40 at screening from a sample collected no more than 42 days prior to study product administration.
* Note: results from specimens collected during screening for any study of an RSV vaccine developed by the Laboratory of Infectious Diseases (LID) (National Institute of Allergy and Infectious Diseases \[NIAID\], National Institutes of Health \[NIH\]) are acceptable. If study product will not be administered the same day as randomization (see the study protocol), it must be administered no more than 42 days after the screening sample is collected.
* Growing normally for age in the opinion of the site clinician in the six months prior to enrollment AND has a current height and weight above the 3rd percentile for age and sex per Centers for Disease Control and Prevention (CDC) World Health Organization (WHO) growth standards.
* Has received routine immunizations appropriate for age (as per national Center for Disease Control Advisory Committee on Immunization Practices \[ACIP\]). Note: COVID-19 vaccination will not be required unless fully licensed for this age group and ACIP-recommended. See study-specific Manual of Procedures for further guidance
* Is expected to be available for the duration of the study.
* If born to an HIV-infected woman, potential participant must have documentation of 2 negative HIV nucleic acid (RNA or DNA) test results from samples collected on different dates with both collected when greater than or equal to 4 weeks of age and at least one collected when greater than or equal to 16 weeks of age, and no positive HIV nucleic acid (RNA or DNA) test; or 2 negative HIV antibody tests, both from samples collected at greater than or equal to 24 weeks of age. If potential participant was breastfed by an HIV-infected woman, each of the sampling times noted above must be measured in weeks after the last exposure to breast milk, rather than weeks of age.
Exclusion Criteria
* Known or suspected HIV infection or impairment of immunological functions.
* Receipt of immunosuppressive therapy, including any systemic, nasal, or inhaled corticosteroids within 28 days of enrollment. Note: Cutaneous (topical) steroid treatment is not an exclusion.
* Any receipt of bone marrow/solid organ transplant.
* Major congenital malformations (such as congenital cleft palate) or cytogenetic abnormalities.
* Previous enrollment in this trial, previous pediatric receipt of a licensed or investigational RSV vaccine, or previous maternal or pediatric receipt of or planned administration of any other anti-RSV product (such as ribavirin or RSV IG or RSV monoclonal antibody \[mAb\]) within 4 months of screening or planned administration of an anti-RSV product between screening and day 56 after enrollment.
* Any previous anaphylactic reaction.
* Any known hypersensitivity to any study product component.
* Heart disease. Note: Potential participants with cardiac abnormalities documented to be clinically insignificant and requiring no treatment may be enrolled.
* Lung disease, including any history of reactive airway disease or medically diagnosed wheezing.
* Member of a household that contains a person with chronic lung disease, including but not limited to chronic obstructive pulmonary disease (COPD), emphysema, or home oxygen use, reactive airway disease or asthma. Note: Asthma or reactive airway disease in a household member is not exclusionary unless the household member has taken oral steroids for asthma management in the past month and/or has been hospitalized for asthma in the past month.
* Member of a household that contains, or will contain, an infant who is less than 4 months of age at the enrollment date through Day 14.
* Member of a household that contains another child/other children who is/are enrolled or is/are scheduled to be enrolled in IMPAACT 2021 on a different date and has/have not completed the Day 56 visit in the same calendar year (i.e., all eligible children from the same household must be enrolled/receive study product on the same date or additional children in the household may be screened, enrolled, and randomized independently after other children in the household complete the Day 56 Visit).
* Member of a household that contains another child who is, or is scheduled to be, enrolled in another study evaluating an intranasal live-attenuated RSV vaccine, AND there has been or will be an overlap in residency during Day 0 to 14 of that other child's participation in the study.
* Member of a household that contains an immunocompromised individual, including, but not limited to:
* a person who has been diagnosed with cancer and who has received chemotherapy within the 12 months prior to enrollment; or
* a person living with a solid organ, cord blood, or bone marrow transplant.
* Shares a daycare room with infants less than 4 months of age, and parent/guardian is unable or unwilling to suspend daycare for 14 days following study product administration.
* Any of the following events at the time of enrollment:
* fever (rectal temperature of greater than or equal to 100.4°F (38°C)), or
* upper respiratory signs or symptoms (including but not limited to rhinorrhea, cough, or pharyngitis) or
* nasal congestion significant enough to interfere with successful study product administration, or
* otitis media.
* Note: if participant is randomized and subsequently noted to have any of the above, study product administration must be deferred per the study protocol.
* Receipt of the following prior to enrollment (start counting backwards with '1' as the day of planned study product administration):
* any inactivated vaccine or live-attenuated rotavirus vaccine within the 14 days prior, or
* any live vaccine, other than rotavirus vaccine, within the 28 days prior, or
* another investigational vaccine or investigational drug within 28 days prior. Note: if COVID-19 vaccine has EUA approval and ACIP recommendation for this age group, it is not considered investigational
* Scheduled administration of the following after planned study product administration (start counting with '1' as the day of planned study product administration):
* inactivated vaccine or live-attenuated rotavirus vaccine within the 14 days after, or
* any live vaccine other than rotavirus in the 28 days after, or
* another investigational vaccine or investigational drug in the 56 days after. Note: if COVID-19 vaccine has EUA approval and ACIP recommendation for this age group, it is not considered investigational.
* Receipt of immunoglobulin, any antibody products, or any blood products within the past 6 months prior to enrollment
* Receipt of any of the following medications within 3 days prior to study enrollment:
* systemic antibacterial, antiviral, antifungal, anti-parasitic, or antituberculous agents, whether for treatment or prophylaxis, or
* intranasal medications, or
* other prescription medication except as listed below
* Permitted concomitant medications (prescription or non-prescription) include nutritional supplements, medications for gastroesophageal reflux, eye drops, and topical medications, including (but not limited to) cutaneous (topical) steroids, topical antibiotics, and topical antifungal agents.
* Born at less than 34 weeks gestation.
* Born between 34 weeks gestation and 36 weeks and 6 days gestation and less than 1 year of age at the time of enrollment.
* Current suspected or documented developmental disorder, delay, or other developmental problem.
* Any previous receipt of supplemental oxygen therapy in a home setting.
* Known or suspected SARS-CoV-2 exposure within the 14 days prior to enrollment. Note: known or suspected SARS-CoV-2 includes a known asymptomatic household member under quarantine for SARS-CoV-2 exposure but without a positive SARS-CoV-2 test.
6 Months
25 Months
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Coleen Cunningham, MD
Role: STUDY_CHAIR
University of California, Irvine
Ruth Karron, MD
Role: STUDY_CHAIR
Center for Immunization Research (CIR), Johns Hopkins Bloomberg School of Public Health (JHSPH)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
David Geffen School of Medicine at UCLA NICHD CRS
Los Angeles, California, United States
University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program
San Diego, California, United States
Univ. of Colorado Denver NICHD CRS
Aurora, Colorado, United States
Emory University School of Medicine NICHD CRS
Atlanta, Georgia, United States
Rush Univ. Cook County Hosp. Chicago NICHD CRS
Chicago, Illinois, United States
Lurie Children's Hospital of Chicago (LCH) CRS
Chicago, Illinois, United States
University of Maryland School of Medicine Center for Vaccine Development CRS
Baltimore, Maryland, United States
The Children's Mercy Hospital CRS
Kansas City, Missouri, United States
Center for Vaccine Development CRS
St Louis, Missouri, United States
SUNY Stony Brook NICHD CRS
Stony Brook, New York, United States
Jacobi Med. Ctr. Bronx NICHD CRS
The Bronx, New York, United States
Duke Vaccine and Trials Unit CRS
Durham, North Carolina, United States
Gamble Center for Clinical Studies CRS
Cincinnati, Ohio, United States
Baylor College of Medicine/ Texas Children's Hospital NICHD CRS
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Informed Consent Form: Protocol Version 3.0
Document Type: Study Protocol: Clarification Memo 1
Document Type: Study Protocol: Letter of Amendment 1
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1 July 2017
Manual for Expedited Reporting of Adverse Events to DAIDS (DAIDS EAE Manual), Version 2.0, January 2010
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
38530
Identifier Type: REGISTRY
Identifier Source: secondary_id
IMPAACT 2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.